Treating hypertension with angiotensin II receptor blockers: A step ahead of blood pressure reduction?

High Blood Pressure and Cardiovascular Prevention

Volumn 12, Issue 1, 2005, Pages 9-15

  Ruilope, Luis M ^a   Volpe, Massimo ^b  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CANDESARTAN HEXETIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; OLMESARTAN; PLACEBO; TELMISARTAN; THIAZIDE DIURETIC AGENT; VALSARTAN;

ACUTE HEART INFARCTION; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG MECHANISM; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; HYPOKALEMIA; KIDNEY DISEASE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; STROKE;

EID: 22844437528     PISSN: 11209879     EISSN: None     Source Type: Journal    
DOI: 10.2165/00151642-200512010-00003     Document Type: Review

References (55)

1. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13
2. Isles CG, Walker LM, Beevers GD, et al. Mortality in patients of the Glasgow blood pressure clinic. J Hypertens 1986; 4: 141-56
3. Blood Pressure Lowering Treatment Trialists' Collaboration. Effect of angiotensin-converting enzyme inhibitors, calcium antagonists, and other blood pressure lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 2000; 355: 1955-64
4. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-62
5. PROGRESS Collaborative Group. Randomized trial of perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41
6. Yusuf S, Sleight P, Dagenais G, et al. Effects of angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE) Study Group. N Engl J Med 2000; 342: 145-53
7. Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362 (9386): 782-8
8. Andersson OK, Almgren T, Persson B, et al. Survival in treated hypertension: follow up study after two decades. BMJ 1998; 317: 167-71
9. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For End-point reduction in hypertension study (LIFE): a randomised trial against atenolol. The LIFE Study Group. Lancet 2002; 359: 995-1003
10. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. The SCOPE Study Group. J Hypertens 2003; 21 (5): 875-86
11. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. The VALUE Trial Group. Lancet 2004; 363 (9426):2022-31
12. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme. Lancet 2003; 362: 759-66
13. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial investigators. A randomized trial of the Angiotensin II Receptor Blocker Valsartan in Congestive Heart Failure (Val-HeFT). N Engl J Med 2001; 345: 1667-75
14. Pfeffer MA, McMurray J, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the Valsartan in Acute Myocardial Infarction Trial (VALIANT). N Engl J Med 2003; 349: 1893-906
15. Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002; 360: 60-75
16. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes: the IDNT Collaborative Study Group. N Engl J Med 2001; 345 (12): 851-60
17. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study investigators. N Engl J Med 2001; 345 (12): 861-9
18. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes: the Irbesartan in patients with type 2 Diabetes and Microalbuminuria (IRMA2) Study Group. N Engl J Med 2001; 345: 870-8
19. Viberti G, Wheeldon NM, for the MicroAlbuminuria Reduction With VALsartan (MARVAL) study investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672-8
20. Timmermans PB. Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol 1999; 15 Suppl. F: 26F-8F
21. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998; 20: 671-81
22. Chobanian A, Bakris G, Black H, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560-71
23. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53
24. Benz JR, Black HR, Graff A, et al. Valsartan and hydrochlorothiazide in patients with essential hypertension: a multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998; 12 (12): 861-6
25. Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000; 13 (4 Pt 1): 418-26
26. Ruilope LM, Coca A, Volpe M, et al. ACE inhibition and cardiovascular mortality and morbidity in essential hypertension: the end of the search or a need for further investigations? Am J Hypertens 2002; 15: 367-71
27. Alderman MH, Madhavan S, Ooi WL, et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324 (16): 1098-104
28. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355: 637-45
29. Volpe M, Musumeci B, De Paolis P, et al. Angiotensin II AT2 receptor subtype: an uprising frontier in cardiovascular disease? J Hypertens 2003; 21: 1429-43
30. Kjeldsen SE, Dahlof B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention For Endpoint reduction (LIFE) substudy. JAMA 2002 Sep 25; 288 (12): 1491-8
31. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction: Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333 (25): 1670-6
32. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease: the PEACE trial investigators. N Engl J Med 2004; 351 (20): 2058-68
33. Teo K, Yusuf S, Sleight P, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ace intolerant subjects with cardiovascular disease (ONTARGET/TRANSCEND) trials. The ONTARGET/TRANSCEND investigators. Am Heart J 2004; 148 (1): 52-61
34. Kizer JR, Dahlof B, Kjeldsen SE, et al. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension 2005; 45: 46-52
35. Lindholm LH, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The LIFE Study Group. Lancet 2002; 359: 1004-10
36. Devereux RB, Dahlof B, Gerdts E, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial. Circulation 2004; 110 (11):1456-62
37. Wachtell K, Olsen MH, Dahlof B, et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J Hypertension 2002; 20: 405-12
38. Olsen MH, Wachtell K, Bella JN, et al. Albuminuria predicts cardiovascular events independently of left ventricular mass in hypertension: a LIFE substudy. J Hum Hypertens 2004; 18: 453-9
39. Ibsen H, Wachtell K, Olsen MH, et al. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens 2004; 22 (9): 1805-11
40. Gerdts E, Oikarinen L, Palmieri V, et al. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Hypertension 2002; 39 (3): 739-43
41. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. The SCORE Project Group. Eur Heart J 2003; 24 (11): 987-1003
42. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet. 2004; 363 (9426): 2049-51
43. Julius S, Kjeldsen SE, Brunner H, et al. VALUE trial: long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens 2003; 16 (7): 544-8
44. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attack trial: major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288: 2981-97
45. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin- converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-6
46. Lindholm LH, Persson M, Alaupovic P, et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21 (8): 1563-74
47. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43 (5): 963-9
48. Sharma AM, Janke J, Gorzelniak K, et al. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002; 40 (5): 609-11
49. Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004; 286 (5): H1597-602
50. Messerli FH, Grossman E, Leonetti G. Antihypertensive therapy and new onset diabetes. J Hypertens 2004; 22 (10): 1845-7
51. Volpe M, Cosentino F, Ruilope LM. Is it time to measure microalbuminuria in hypertension? J Hypertens 2003; 21 (7): 1213-20
52. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy: the Diabetics Exposed to Telmisartan and Enalapril (DETAIL) Study Group. N Engl J Med 2004; 351 (19): 1952-61
53. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. The CHARM Investigators and Committees. Lancet 2003; 362: 772-6
54. McMurray JJ, Ostergen J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. The CHARM Investigators and Committees. Lancet 2003; 362: 767-71
55. Yusuf S, Pfeffer MA, Swedberg K, et al. CHARM-preserved effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. The CHARM Investigators and Committees. Lancet 2003; 362 (9386): 777-81